Bachem announced that it is calling for an Extraordinary General Meeting in order to create the grounds for strengthening the company’s capital base for investments into sustainable growth. The Board of Directors therefore proposes the creation of up to one million new shares through an authorized capital increase.

 

Bachem is the world market leader for peptides with fifty years of experience in the manufacturing and development of these specialized molecules, which are used as an active pharmaceutical ingredient in a number of medicines. The company intends to further expand its leadership position in a rapidly growing peptide market and to become a leading provider of oligonucleotides, a new therapeutic platform on the basis of DNA or RNA. Bachem is a key contributor to the global supply with innovative medicines and is pursuing a sustainable strategy of profitable growth.

 

In view of promising long-term growth prospects, Bachem intends to accelerate the expansion of its capacity across all its sites and business areas. In the next five years the company plans investments of over CHF 500 million.

 

Bachem is investing in the construction of the company’s hitherto largest manufacturing facility in Bubendorf, the expansion of automated manufacturing solutions, equipment and technology across all its sites, as well as the establishment of an additional manufacturing site. A site search within Switzerland is ongoing.